CoStar Group, a large-cap real estate data and marketplace provider, has seen its stock significantly underperform the broader real estate sector, with shares down roughly 65% from its 52-week high and 49.1% year-to-date. Despite the poor stock performance, the company reported strong Q1 2026 earnings, with revenue up 23% and adjusted EBITDA more than doubling. Analysts remain optimistic with a "Moderate Buy" rating and a potential upside of 41.2% from current levels.

PPG Industries (PPG) is a large-cap specialty chemicals company with a global presence, valued at $25.2 billion. While PPG has gained 6.7% over the past three months, it has underperformed the Nasdaq Composite's 10.9% gains. However, its year-to-date performance shows a 10.3% rise, outpacing the Nasdaq's 8.3%, and analysts maintain a "Moderate Buy" rating with an 8.8% upside potential.

Citigroup (C) is reportedly in talks with major private companies to launch tokenized shares. The banking giant is developing a system for wealthy and institutional clients to access these digital assets. This move indicates Citi's potential engagement in the growing blockchain and digital asset space.

Teradyne Robotics is showcasing a wide range of production-ready physical AI applications at Automate 2026, moving beyond conceptual hype to deployable solutions. These innovations, featuring their Universal Robots (UR) and Mobile Industrial Robots (MiR) platforms, aim to automate complex tasks in dynamic environments, with PolyScope X forming the foundational software layer. The company highlights solutions for electronics manufacturing, AI data centers, and various industrial applications, demonstrating how physical AI can enable robots to work effectively in real-world messy realities.

Omnissa has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Digital Employee Experience (DEX) Management Tools for the second consecutive year. The company was also highly ranked in the Critical Capabilities report, validating its AI-driven approach to unifying insights, proactively resolving issues, and delivering high-quality digital experiences. Omnissa emphasizes the increasing complexity of IT environments due to AI sprawl and the need for comprehensive DEX solutions.

MetLife has introduced the Non-Qualified Assignment Flex Agreement (NQA-FA), a new deferred payment solution for non-physical injury claims. This solution allows for flexible settlement structures, including deferred start dates and customized payment schedules, addressing a growing need for adaptable settlements in cases like employment litigation and contract disputes. Unlike traditional structures, the NQA-FA is not subject to IRS Section 72(u) requirements, enabling payment deferrals beyond one year and providing greater control for attorneys and brokers.

Compeer Financial and PepsiCo have partnered to launch RegenLend, a pilot leasing program designed to help farmers adopt strip-till practices by offsetting equipment costs. PepsiCo will cover two annual lease payments, reducing the financial barrier for farmers seeking to improve soil health and sustainability. This initiative, supported by the Environmental Defense Fund and Soil and Water Outcomes Fund, aims to bridge the investment gap for soil conservation technology.

Williams-Sonoma (WSM) has declared a quarterly dividend of $0.76 per share, totaling $3.04 annualized, which represents an annual yield of 1.5 percent. This dividend is payable on August 21, 2026, to shareholders of record as of July 17, 2026, with an ex-dividend date of July 16, 2026. The stock's current price is $206.94 and its overall analyst rating is SELL.

The Black Music Action Coalition (BMAC), in partnership with Live Nation’s School of Live, announced a special touring edition of BMAC Live. This program offers aspiring music industry professionals exclusive behind-the-scenes access to select stops of The R&B Tour, featuring Chris Brown and USHER. Participants will learn about live event production, venue operations, and touring logistics from industry professionals.

Boston Scientific (BSX) has experienced a significant de-rating in 2026, with share prices down nearly 50%, despite most analysts maintaining bullish ratings. The dip is attributed to reduced growth expectations for the company's Watchman left atrial appendage closure franchise. BTIG and Canaccord have both lowered their price targets, but still recommend "Buy" ratings, aligning with the overall positive Wall Street sentiment for the medical device manufacturer.